Kevin Church Athira Pharma, Inc. (ATHA) insider trading activity

Kevin Church is CHIEF SCIENTIFIC OFFICER of Athira Pharma, Inc.. Currently has a direct ownership of 130,761 shares of ATHA, which is worth approximately $70,610. The most recent transaction as insider was on Jan 02, 2025, when has been sold 8,510 shares (Common Stock) at a price of $0.56 per share, resulting in proceeds of $4,765. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 131K

41.08% 3M change

79.94% 12M change

Total Value Held $70,610

KEVIN CHURCH Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	SELL Open market or private sale	$4,765 $0.56 p/Share	8,510 Reduced 6.11%	130,761 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	36,667 Added 20.84%	139,271 Common Stock
Nov 18 2024	BUY Grant, award, or other acquisition	$5,456 $0.55 p/Share	9,920 Added 8.82%	102,604 Common Stock
Sep 05 2024	SELL Open market or private sale	$1,439 $0.57 p/Share	2,525 Reduced 2.65%	92,684 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	-	10,000 Added 9.5%	95,209 Common Stock
May 20 2024	BUY Grant, award, or other acquisition	$6,637 $1.34 p/Share	4,953 Added 5.49%	85,209 Common Stock
Nov 20 2023	BUY Grant, award, or other acquisition	$4,551 $1.34 p/Share	3,397 Added 4.47%	72,668 Common Stock
May 18 2023	BUY Grant, award, or other acquisition	$1,949 $2.41 p/Share	809 Added 1.15%	69,271 Common Stock
Mar 24 2023	BUY Exercise of conversion of derivative security	$8,653 $1.35 p/Share	6,410 Added 8.56%	68,462 Common Stock
Jan 05 2023	SELL Open market or private sale	$7,018 $2.91 p/Share	2,412 Reduced 2.92%	80,256 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	10,000 Added 10.79%	82,668 Common Stock
Nov 18 2022	BUY Grant, award, or other acquisition	$1,800 $2.74 p/Share	657 Added 1.05%	62,052 Common Stock
Oct 28 2022	BUY Exercise of conversion of derivative security	$4,995 $1.35 p/Share	3,700 Added 5.68%	61,395 Common Stock
Jun 23 2022	SELL Open market or private sale	$7,032 $2.69 p/Share	2,614 Reduced 4.33%	57,695 Common Stock
Jun 22 2022	BUY Grant, award, or other acquisition	-	10,000 Added 14.22%	60,309 Common Stock
Jun 08 2022	BUY Exercise of conversion of derivative security	$3,375 $1.35 p/Share	2,500 Added 4.73%	50,309 Common Stock
May 18 2022	BUY Grant, award, or other acquisition	$1,716 $7.06 p/Share	243 Added 0.51%	47,809 Common Stock
Feb 18 2022	BUY Exercise of conversion of derivative security	$3,751 $1.19 p/Share	3,152 Added 6.21%	47,566 Common Stock
Nov 18 2021	BUY Grant, award, or other acquisition	$1,201 $12.51 p/Share	96 Added 0.22%	44,414 Common Stock
Jun 08 2021	BUY Exercise of conversion of derivative security	$3,278 $1.04 p/Share	3,152 Added 6.67%	44,133 Common Stock

Kevin Church

CHIEF SCIENTIFIC OFFICER

Bothell, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATHA shares.

Notify only if

Value

Insider Trading

Get notified when an Athira Pharma, Inc. insider buys or sells ATHA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Athira Pharma, Inc.

Track Activities on ATHA

Account